China Removes Tariffs on Many African Imports for Two Years to Boost Trade
China has lifted tariffs on many imports from Africa for the next two years. The move comes as Beijing expands its influence on the continent while the U.S. appears to be pulling back.
Al JazeeraBeijing has recently removed tariffs on many imports from Africa for the next two years. The tariff-free access applies to many African products and has renewed hopes of industrial growth on the continent. China is Africa’s largest trading partner.
Chinese exports to Africa far exceed African exports to China, and many African nations remain heavily reliant on exporting raw commodities while importing manufactured goods. Chinese money has helped finance roads, railways and ports across Africa for more than a decade.
U.S. Appears to be pulling back from the continent. China wants access to Africa’s resources, and the continent wants to build industries and jobs and move up the value chain. Trade between the two sides remains uneven despite the tariff removal.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
prnewswire.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
insidermonkey.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…